Table 2 The short-term efficacy comparison between case and control groups.

From: Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial

 

Case Group

Control Group

P-Value

CR

0

0

 

PR

11

1

 

SD

19

5

 

PD

9

23

 

DCR(CR + PR + SD)

30 (76.9%)

6 (20.7%)

p < 0.001

ORR (CR + PR)

11 (28.2%)

1 (3.4%)

p < 0.001

Back to article page